These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8774418)

  • 41. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.
    Vijayaraghavan S; Maetzler W; Reimold M; Lithner CU; Liepelt-Scarfone I; Berg D; Darreh-Shori T
    Alzheimers Dement; 2014 Sep; 10(5):530-540.e1. PubMed ID: 23978325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
    Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alzheimer's disease: Elevated pigment epithelium-derived factor in the cerebrospinal fluid is mostly of systemic origin.
    Lang V; Zille M; Infante-Duarte C; Jarius S; Jahn H; Paul F; Ruprecht K; Pina AL
    J Neurol Sci; 2017 Apr; 375():123-128. PubMed ID: 28320113
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
    Appleyard ME; McDonald B
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1074-8. PubMed ID: 1469405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
    BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls.
    Struyfs H; Molinuevo JL; Martin JJ; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2014; 41(3):903-9. PubMed ID: 24705548
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease.
    Kester MI; van der Flier WM; Mandic G; Blankenstein MA; Scheltens P; Muller M
    J Alzheimers Dis; 2010; 20(4):1083-90. PubMed ID: 20413898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
    Iqbal K; Flory M; Khatoon S; Soininen H; Pirttila T; Lehtovirta M; Alafuzoff I; Blennow K; Andreasen N; Vanmechelen E; Grundke-Iqbal I
    Ann Neurol; 2005 Nov; 58(5):748-57. PubMed ID: 16247771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
    Buerger K; Frisoni G; Uspenskaya O; Ewers M; Zetterberg H; Geroldi C; Binetti G; Johannsen P; Rossini PM; Wahlund LO; Vellas B; Blennow K; Hampel H
    Exp Gerontol; 2009 Sep; 44(9):579-85. PubMed ID: 19539742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.
    Lewczuk P; Esselmann H; Otto M; Maler JM; Henkel AW; Henkel MK; Eikenberg O; Antz C; Krause WR; Reulbach U; Kornhuber J; Wiltfang J
    Neurobiol Aging; 2004 Mar; 25(3):273-81. PubMed ID: 15123331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.
    Ganzer S; Arlt S; Schoder V; Buhmann C; Mandelkow EM; Finckh U; Beisiegel U; Naber D; Müller-Thomsen T
    J Neural Transm (Vienna); 2003 Oct; 110(10):1149-60. PubMed ID: 14523627
    [TBL] [Abstract][Full Text] [Related]  

  • 53. O-glycosylation on cerebrospinal fluid and plasma apolipoprotein E differs in the lipid-binding domain.
    Flowers SA; Grant OC; Woods RJ; Rebeck GW
    Glycobiology; 2020 Jan; 30(2):74-85. PubMed ID: 31616924
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro.
    Vuletic S; Peskind ER; Marcovina SM; Quinn JF; Cheung MC; Kennedy H; Kaye JA; Jin LW; Albers JJ
    J Neurosci Res; 2005 May; 80(3):406-13. PubMed ID: 15795933
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship between the diagnosis method of neuronal dysfunction (DIMENSION) and brain pathology in the early stages of Alzheimer's disease.
    Kouzuki M; Asaina F; Taniguchi M; Musha T; Urakami K
    Psychogeriatrics; 2013 Jun; 13(2):63-70. PubMed ID: 23909962
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease.
    Shuvaev VV; Laffont I; Serot JM; Fujii J; Taniguchi N; Siest G
    Neurobiol Aging; 2001; 22(3):397-402. PubMed ID: 11378244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients.
    Rösler N; Wichart I; Jellinger KA
    Neurosci Lett; 2001 Feb; 299(1-2):117-20. PubMed ID: 11166952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.